bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2019-64-2-234-237bloodjour-142Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCASE REPORTSПРИАПИЗМ КАК ПЕРВЫЙ ПРИЗНАК ХРОНИЧЕСКОГО МИЕЛОЛЕЙКОЗАPRIAPISM AS THE FIRST SIGN OF CHRONIC MYELOID LEUKEMIAhttps://orcid.org/0000-0003-4768-3841РустамовМ. Н.RustamovM. N.

Рустамов Маариф Назир Оглы, врач-уролог, аспирант института урологии и репродуктивного здоровья человека

тел.:+7(951)066-81-93; AZ 1000, г. Баку, ул. Нахчивани, 13.

Maarif Nazir Ogly Rustamov, Urologist, Post-graduate Researcher, Institute of Urology and Reproductive Health

tel.: + 7 (951) 066-81-93; AZ 1000, Baku, Nahyvani str., 13.

rustamovmaarif@gmail.comhttps://orcid.org/0000-0003-0990-9133ГусейновГ. Р.HuseynovG. R.

Гусейнов Габиль, врач-уролог, резидент кафедры урологии 

тел.: (+994) 506-020-575

Gabil Huseynov, Urologist, Resident of Deptartment of Urology

drqabilhuseynov@gmail.comhttps://orcid.org/0000-0002-3146-9931АхмедовИ. С.AkhmedovI. S.

Ахмедов Ильхам, врач уролог-андролог, президент общества андрологов Азербайджана, доктор медицинских наук, профессор кафедры урологии

Ilham Akhmedov, Urologist-Andrologist, Dr. Sci. (Med.), President of Azerbaijan Andrology Society Prof., Department of Urology

doctor.ilham@hotmail.comКлиника Medera HospitalАзербайджанMedera HospitalAzerbaijanАзербайджанский медицинский университетАзербайджанAzerbaijan Medical UniversityAzerbaijan201904102019642234237Copyright © Рустамов М.Н., Гусейнов Г.Р., Ахмедов И.С., 20192019Рустамов М.Н., Гусейнов Г.Р., Ахмедов И.С.Rustamov M.N., Huseynov G.R., Akhmedov I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/142Введение

Введение. Приапизм — длительная болезненная эрекция, которая продолжается свыше четырех часов, сохраняющаяся после прекращения сексуальной стимуляции или не связанная с ней. Приапизм может быть первым клиническим проявлением хронического миелоидного лейкоза (ХМЛ).

Цель клинического наблюдения — описать ишемический приапизм, возникший у больного с не диагностированным ранее ХМЛ.

Основные сведения

Основные сведения. Представлено наблюдение ишемического приапизма длительностью 18 часов, возникшего у больного с не диагностированным ранее ХМЛ. В последующем диагноз ХМЛ был установлен на основании исследования периферической крови и костного мозга. Лечебная тактика состояла из немедленной пункционной аспирации крови из кавернозных тел и внутрикавернозной инъекции раствора фенилэфрина. После купирования приапизма проводилась терапия ХМЛ, которая позволила избежать рецидива приапизма у больного.

Introduction

Introduction. Priapism is a prolonged painful erection lasting for more than four hours, which either persists after the termination of sexual stimulation or is not associated therewith. Priapism may be the first clinical manifestation of chronic myeloid leukemia (CML).

Aim

Aim. To describe a clinical case of ischemic priapism that occurred in a patient with a previously undiagnosed CML.

General findings

General findings. We present a clinical observation of ischemic priapism having lasted for 18 hours, which occurred in a patient with a previously undiagnosed CML. The diagnosis of CML was subsequently established on the basis of a study of peripheral blood and bone marrow. The therapeutic tactics consisted in an immediate puncture aspiration of blood from the corpora cavernosa and an intracavernous injection of a phenylephrine solution. After priapism had been relieved, an CML therapy was applied, which allowed the recurrence of priapism in the patient to be avoided.

приапизмхронический миелоидный лейкозрriapismchronic myeloid leukemiaReferencesSalonia A., Eardley I., Giuliano F., et al. European Association of Urology guidelines on priapism. Eur Urol. 2014; 65(2): 480–9. DOI: 10.1016/j.eururo.2013.11.008Salonia A., Eardley I., Giuliano F., et al. European Association of Urology guidelines on priapism. Eur Urol. 2014; 65(2): 480–9. DOI: 10.1016/j.eururo.2013.11.008Eland I.A., van der Lei J., Stricker B.H., Sturkenboom M.J. Incidence of priapism in the general population. Urology. 2001; 57 (5): 970–2.Eland I.A., van der Lei J., Stricker B.H., Sturkenboom M.J. Incidence of priapism in the general population. Urology. 2001; 57 (5): 970–2.Metawea B., El-Nashar A.R., Gad-Allah A., et al. Intracavernous papaverine/ phentolamine-induced priapism can be accurately predicted with color Doppler ultrasonography. Urology. 2005; 66(4): 858–60.Metawea B., El-Nashar A.R., Gad-Allah A., et al. Intracavernous papaverine/ phentolamine-induced priapism can be accurately predicted with color Doppler ultrasonography. Urology. 2005; 66(4): 858–60.Keoghane S.R., Sullivan M.E., Miller M.A. The aetiology, pathogenesis and management of priapism. BJU Int. 2002; 90(2): 149–54.Keoghane S.R., Sullivan M.E., Miller M.A. The aetiology, pathogenesis and management of priapism. BJU Int. 2002; 90(2): 149–54.Montague D.K., Jarow J., Broderick G.A., et al. American Urological Association guideline on the management of priapism. J Urol. 2003; 170 (4 Pt 1):1318– 24. DOI: 10.1097/01.ju.0000087608.07371.caMontague D.K., Jarow J., Broderick G.A., et al. American Urological Association guideline on the management of priapism. J Urol. 2003; 170 (4 Pt 1):1318– 24. DOI: 10.1097/01.ju.0000087608.07371.caHuei T.J., Lip H.T., Shamsuddin O. A rare presentation of chronic myeloid leukaemia with priapism treated with corporoglandular shunting. Med J Malaysia. 2018; 73(6): 420–2.Huei T.J., Lip H.T., Shamsuddin O. A rare presentation of chronic myeloid leukaemia with priapism treated with corporoglandular shunting. Med J Malaysia. 2018; 73(6): 420–2.Dhar J., Dhar J., Chhabra G., et al. Priapism as a Debut Presentation of Chronic Myeloid Leukemia J Coll Physicians Surg Pak. 2019; 29(1): 78–80. DOI: 10.29271/jcpsp.2019.01.78Dhar J., Dhar J., Chhabra G., et al. Priapism as a Debut Presentation of Chronic Myeloid Leukemia J Coll Physicians Surg Pak. 2019; 29(1): 78–80. DOI: 10.29271/jcpsp.2019.01.78Kumar P., Rahman K., Kumari S., et al. Priapism as a rare presentation of chronic myeloid leukemia. J Cancer Res Ther. 2018; 14(6): 1442–3. DOI:10.4103/0973- 1482.199388Kumar P., Rahman K., Kumari S., et al. Priapism as a rare presentation of chronic myeloid leukemia. J Cancer Res Ther. 2018; 14(6): 1442–3. DOI:10.4103/0973- 1482.199388Khan A., Shafiq I., Shah M.H., et al. Chronic myeloid leukaemia presenting as priapism: A case report from Khyber Pakhtunkhwa. J Pak Med Assoc. 2018; 68(6): 942–4. PMID: 30323364Khan A., Shafiq I., Shah M.H., et al. Chronic myeloid leukaemia presenting as priapism: A case report from Khyber Pakhtunkhwa. J Pak Med Assoc. 2018; 68(6): 942–4. PMID: 30323364Shaeer O.K., Shaeer K.Z., AbdelRahman I.F., et al. Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature. J Sex Med. 2015; 12(3): 827–34. DOI: 10.1111/jsm.12812Shaeer O.K., Shaeer K.Z., AbdelRahman I.F., et al. Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature. J Sex Med. 2015; 12(3): 827–34. DOI: 10.1111/jsm.12812Minckler M.R., Conser E., Figueroa J.J., et al. The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia Case Rep Emerg Med. 2017; 2017: 2656203. DOI: 10.1155/2017/2656203Minckler M.R., Conser E., Figueroa J.J., et al. The Semantics of Priapism and the First Sign of Chronic Myeloid Leukemia Case Rep Emerg Med. 2017; 2017: 2656203. DOI: 10.1155/2017/2656203Rodgers R., Latif Z., Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br. J. Haematol. 2012; 158: 155–164. DOI: 10.1111/j.1365-2141.2012.09151.xRodgers R., Latif Z., Copland M. How I manage priapism in chronic myeloid leukaemia patients. Br. J. Haematol. 2012; 158: 155–164. DOI: 10.1111/j.1365-2141.2012.09151.xGogia A., Sharma A., Raina V., Gupta R. Priapism as an initial presentation of chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 53(8): 1638–9. DOI: 10.3109/10428194.2012.656636Gogia A., Sharma A., Raina V., Gupta R. Priapism as an initial presentation of chronic lymphocytic leukemia. Leuk Lymphoma. 2012; 53(8): 1638–9. DOI: 10.3109/10428194.2012.656636Strobel E., Howe J., Bäcker U., et al. Therapeutic lymphapheresis in leukostasis-induced priapism. Dtsch Med Wochenschr. 1987; 112(51–52): 1984–5.Strobel E., Howe J., Bäcker U., et al. Therapeutic lymphapheresis in leukostasis-induced priapism. Dtsch Med Wochenschr. 1987; 112(51–52): 1984–5.Castagnetti M., Sainati L., Giona F., et al. Conservative Management of Priapism Secondary to Leukemia. Pediatr Blood Cancer. 2008; 51(3): 420-3 DOI: 10.1002/pbc.21628Castagnetti M., Sainati L., Giona F., et al. Conservative Management of Priapism Secondary to Leukemia. Pediatr Blood Cancer. 2008; 51(3): 420-3 DOI: 10.1002/pbc.21628Mentzel H.J, Kentouche K., Doerfel C., et al. High-flow priapism in acute lymphatic leukaemia. Pediatr Radiol. 2004; 34 (7):560-3. DOI: 10.1007/s00247-003-1124-1Mentzel H.J, Kentouche K., Doerfel C., et al. High-flow priapism in acute lymphatic leukaemia. Pediatr Radiol. 2004; 34 (7):560-3. DOI: 10.1007/s00247-003-1124-1Schreibman S.M., Gee T.S., Grabstald H. Management of priapism in patients with chronic granulocytic leukemia. J Urol. 1974; 111: 786–8.Schreibman S.M., Gee T.S., Grabstald H. Management of priapism in patients with chronic granulocytic leukemia. J Urol. 1974; 111: 786–8.Cherian J., Rao A.R., Thwaini A., et al. Medical and surgical management of priapism. Postgrad Med. J. 2006; 82: 89–94.Cherian J., Rao A.R., Thwaini A., et al. Medical and surgical management of priapism. Postgrad Med. J. 2006; 82: 89–94.Ergenc H., Varım C., Karacaer C., Çekdemir D. Chronic myeloid leukemia presented with priapism: Effective management with prompt leukapheresis. Niger J Clin Pract. 2015; 18(6): 828–30. DOI: 10.4103/1119-3077.163282Ergenc H., Varım C., Karacaer C., Çekdemir D. Chronic myeloid leukemia presented with priapism: Effective management with prompt leukapheresis. Niger J Clin Pract. 2015; 18(6): 828–30. DOI: 10.4103/1119-3077.163282

The authors declare that there are no conflicts of interest present.